Cansick Janette C, Lennon Rachel, Cummins Carole L, Howie Alexander J, McGraw Mary E, Saleem Moin A, Tizard E Jane, Hulton Sally-Anne, Milford David V, Taylor C Mark
Department of Paediatric Nephrology, Birmingham Children's Hospital, Birmingham, UK.
Nephrol Dial Transplant. 2004 Nov;19(11):2769-77. doi: 10.1093/ndt/gfh484. Epub 2004 Sep 22.
Prognostic factors and outcome are incompletely known in childhood mesangiocapillary glomerulonephritis (MCGN). This study aimed to correlate renal outcome with clinical and histopathological variables.
We conducted a two-centre retrospective analysis of children with MCGN.
Fifty-three children presented at a mean age of 8.8 years (range: 13 months-15 years). They were followed for a median of 3.5 years (range: 0-17 years). Histological classification identified 31 type 1, 14 type 2, two type 3 and six undetermined type. Mean renal survival [time to end-stage renal failure (ESRF)] was projected to be 12.2 years [confidence interval (CI): 9.7-14.6 years]. Five and 10 year renal survival was 92% (CI: 88-100%) and 83% (CI: 74-92%), respectively. Those with nephrotic syndrome at presentation had mean renal survival of 8.9 years (CI: 7.1-10.7 years) vs 13.6 years for those without (CI: 10.8-16.5 years) (P = 0.047). The mean estimated glomerular filtration rate (eGFR) at 1 year in those who progressed to ESRF was 52 vs 98 ml/min/1.73 m2 in those who did not (P < 0.001). Chronic damage scored on the first biopsy in 31 children (one centre) was positively associated with adverse renal outcome at 5 years: <20% was associated with 100% and > or =20% with 71% 5-year renal survival (P = 0.006). In 29 children treated with steroid there was a higher proportion (76%) with reduced eGFR at presentation and a significantly higher incidence of nephrotic syndrome (P = 0.002) and hypertension (P = 0.037). There were no significant differences in outcome eGFR, hypertension or proteinuria.
Nephrotic syndrome at presentation and subnormal eGFR at 1 year were adverse features. The finding that structural disease at onset predicted poor renal outcome at 5 years has implications for the design of therapeutic trials. Treatment of MCGN was variable and not evidence-based.
儿童系膜毛细血管性肾小球肾炎(MCGN)的预后因素和结局尚不完全清楚。本研究旨在将肾脏结局与临床和组织病理学变量进行关联分析。
我们对患有MCGN的儿童进行了一项双中心回顾性分析。
53名儿童就诊时的平均年龄为8.8岁(范围:13个月至15岁)。他们的中位随访时间为3.5年(范围:0至17年)。组织学分类确定为1型31例、2型14例、3型2例和未确定类型6例。预计平均肾脏生存期[至终末期肾衰竭(ESRF)的时间]为12.2年[置信区间(CI):9.7至14.6年]。5年和10年肾脏生存率分别为92%(CI:88%至100%)和83%(CI:74%至92%)。就诊时患有肾病综合征的患者平均肾脏生存期为8.9年(CI:7.1至10.7年),而未患肾病综合征的患者为13.6年(CI:10.8至16.5年)(P = 0.047)。进展至ESRF的患者1年时的平均估计肾小球滤过率(eGFR)为52,而未进展者为98 ml/min/1.73 m²(P < 0.001)。31名儿童(一个中心)首次活检时的慢性损伤评分与5年时不良肾脏结局呈正相关:<20%与100%的5年肾脏生存率相关,≥20%与71%的5年肾脏生存率相关(P = 0.006)。在29名接受类固醇治疗的儿童中,就诊时eGFR降低的比例较高(76%),肾病综合征(P = 0.002)和高血压(P = 0.037)的发生率显著更高。在结局、eGFR、高血压或蛋白尿方面无显著差异。
就诊时患有肾病综合征和1年时eGFR低于正常是不良特征。发病时的结构性疾病预示5年时肾脏结局不佳这一发现对治疗试验的设计具有启示意义。MCGN的治疗方法不一且缺乏循证依据。